Researchers provide a rationale for the clinical development of fadraciclib in chronic lymphocytic leukemia, either alone or in combination with a Bcl-2 antagonist.
[Leukemia]
Sorry, but the selected Zotpress account can't be found.
Home Newsletters Hematopoiesis News Cyclin-Dependent Kinase Inhibitor Fadraciclib (CYC065) Depletes Anti-apoptotic Protein and Synergizes with Venetoclax...
